TLDR
Older adults who received a shingles shot were less likely to be diagnosed with memory loss later. The result was similar in two large healthcare groups, but it does not prove the shot prevents memory loss.
Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Study Aim
The authors examined whether herpes zoster (HZ; shingles) vaccination was associated with fewer new dementia diagnoses among adults aged 65 or older. They also tested whether age, race, HZ infection, or antiviral treatment changed this association. A secondary aim assessed Alzheimer’s disease (AD; the most common dementia type). The study asked whether a shingles shot might be linked with fewer later memory-loss diagnoses.
2 Study Design
The study used a retrospective cohort design (following existing records over time). Researchers analyzed Veterans Health Administration (VHA) records for 136,016 patients and MarketScan claims for 172,790 patients. Participants were at least 65 years old, had no dementia during the previous two years, and had at least three well visits. Vaccination status was measured at 2011 or 2012 index dates. New dementia required diagnosis codes on two separate days. Propensity scores (estimated vaccination probabilities) and inverse probability of treatment weighting (IPTW; rebalancing groups statistically) addressed differences between vaccinated and unvaccinated patients. VHA models accounted for death, while MarketScan used Cox proportional-hazards models (comparing risks over time). The researchers compared two large groups using existing healthcare records over several years.
3 Findings
The study reports lower dementia risk after vaccination in both cohorts: 31% lower overall in the combined analysis, with hazard ratios (HRs; relative risks over time) of 0.69 in VHA and 0.65 in MarketScan. Vaccination was also linked to 25% lower AD risk in VHA and 30% lower risk in MarketScan. Later HZ infection or antiviral treatment did not explain the association. MarketScan participants aged 65–69 showed no association, while VHA participants aged 70–74 had the weakest association. Effects did not differ by race. The authors suggest immune effects beyond preventing shingles might protect the brain. They recommend prospective studies and clinical trials, because retrospective research cannot prove causation. A shingles shot was linked with fewer later memory-loss diagnoses, but more research is needed to show whether it truly prevents them.